Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Prospect Capital Corporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Prospect Capital Corporation trades at $1.59 (market cap $891.47M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock and Prospect Capital Corporation are close in size by market cap, and Prospect Capital Corporation pays a 25.15% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Prospect Capital Corporation for 78 Days on average.
| MRVI | PSEC | |
|---|---|---|
Market Cap | $972.90M | $891.47M |
Volume | 4,325,710 | 4,809,352 |
Sector | Health | Financials |
52-Week High | $9.00 | $3.05 |
52-Week Low | $2.83 | $1.60 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $1.08B | $2.65B |
Dividend Yield | — | 25.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PSEC trades at $1.60, down 7.51% with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly earnings have consistently beaten expectations, though the company maintains a modest 25% analyst buy rating amid ongoing dividend distributions of $0.04 monthly.
Outlook remains cautious due to negative cash flow and volatile revenue patterns. The 18%+ dividend yield attracts income investors but carries sustainability risks given declining NAV and portfolio contraction. Analyst consensus leans neutral with 55% hold ratings, reflecting concerns about long-term performance stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
